Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome.

Michael J. Keating(The University of Texas MD Anderson Cancer Center), Emil J. Freireich(Unknown), José M. Trujillo(National Institutes of Health), H. Kantarjian(The University of Texas MD Anderson Cancer Center), E. A. Gehan(The University of Texas MD Anderson Cancer Center), R S Walters(Breast Cancer Care), Terry L. Smith(Virginia Commonwealth University), Ann Cork(The University of Texas MD Anderson Cancer Center), K. B. McCredie(The University of Texas MD Anderson Cancer Center)
PubMed
July 1, 1988
Cited by 218

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
|Blood|1997|1.2k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
|Blood|2002|946